Twist Bioscience touched about $192 intraday, a new 52-week high, before retreating toward $183. The advance comes in a nine-week, five-leg rally with typical 10-15% pullbacks, signaling reaccumulation rather than a single parabolic move. While momentum remains intact, the prolonged streak without consolidation warrants caution and potential catalysts like earnings or product updates for a sustained move.
Anthropic named Twist Bioscience an independent evaluator for an AI-driven protein design campaign, triggering a near-term stock move. The news provides external validation of TWST's AI-enabled biology capabilities and could attract new partners, though no financial terms were disclosed. The stock reaction may fade absent concrete contracts, keeping upside contingent on tangible milestones.
Twist Bioscience reported an adjusted loss that missed expectations, but its revenue surpassed forecasts, indicating strong growth potential. The company raised its fiscal 2026 sales guidance, reflecting positive momentum across its portfolio and expanded capabilities in AI-enabled drug discovery.
Twist Bioscience has released its financial results for Q2 fiscal 2026 and will hold a conference call today to discuss key business updates. Investors should monitor the call for insights on performance and strategic directions that could influence TWST's share price.
Twist Bioscience Corporation (TWST) outperformed sales expectations in its first quarter, signaling positive growth momentum. This strong financial performance is likely to enhance investor confidence and may stimulate upward price action in the stock.
Twist Bioscience Corporation reported a first-quarter 2026 loss of 50 cents per share, aligning with Wall Street expectations. This performance suggests stability for the company, which could position it favorably amid investing trends.
